Wednesday, 1 April 2020

Dr Reddy’s Lab Gains On Launching Somazina Drug In India

Updated: May 29, 2015 11:44 pm

Shares of Dr Reddy’s Laboratories were trading higher by nearly 3% at Rs 3,589 on the NSE after the drug maker announced the launch of Somazina, an innovator brand of Citicoline in the Indian market. The drug is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infraction, or who have undergone a brain surgery or have suffered from head injuries. Dr Reddy’s has partnered with the global innovator of Citicoline, Ferrer International S A of Spain to make Somazina available in India, the company said in a press release.

Leave a Reply

Your email address will not be published. Required fields are marked *

Archives

Categories